**Core tip:** This systematic review determines the most statistically significant factors that increase a patient's risk of developing lower limb periprosthetic joint infections. Reviewing all relevant papers until November 2016 through international databases, we have included 27 original studies. The results include multiple factors relating to the patient and the Institute, as well as post-operative predictors and causes of infection. This ultimately reiterates the importance of optimising the patients pre-operatively by addressing modifiable risk factors (such as their immunosuppression, nutrition, diabetes, and smoking), and develops strategies to limit the impact of non-modifiable factors.

INTRODUCTION
============

Chronic periprosthetic joint infections (PJI) have received increasing interest in the medical literature as the profession has acknowledged the real-life implications to the patient and the health service\[[@B1],[@B2]\]. The treatment of PJI is costly to the health service with strain upon limited resources as multiple operations and trials of antibiotic therapy may be attempted. But the cost to the patient is greatest, with loss or reduced joint function, deterioration in their physical and psychological health, and loss in trust with the profession.

Prevention is key. Despite improved outcomes following the various treatment modalities for treating established infections today, the patient has to endure the consequences of the infection\[[@B3]\]. Prior to the initial surgery it is imperative the patient is medically optimised and any reversible risk factors be corrected. Such risk factors are well known such as diabetes\[[@B4]\], systemic infections\[[@B5]\], and immunocompromise\[[@B6]\].

However, risk factors vary and are dependent upon the patient cohort, and often findings from isolated studies are not transferable. Therefore, we undertook a systematic review of the literature to determine overall predictive factors that increase a patient's risk of developing a lower limb PJI, and determine which risk factors are most predictive of infection.

In this review, we categorised risk factors in order to better understand the relative role of the host, of the healthcare provider, and of post-surgical conditions, the latter acting more as prognostic factors since the surgical procedure has already taken place. To this aim, we have subdivided known risk factors for PJI in three groups: (1) those relating to the host (host-related risk factors); (2) those that are related to the treatment provider and to the surgical environment (provider-related risk factors); and (3) those that arise from clinical interventions, increasing the patient's inherent risk (post-surgical risk factors). We have then compared the absolute number of risk factors in each main category, scored them according to their relative weight and divided in "modifiable" and "non-modifiable" risk factors.

MATERIALS AND METHODS
=====================

This systematic review included full-text studies that reviewed risk factors of developing either a hip or knee PJI following a primary arthroplasty published from January 1998 to November 2016. These were identified through international databases, such as EMBASE, PubMed/MEDLINE, MEDLINE Daily Update, MEDLINE In-Process, Google Scholar, SCOPUS, CINAHL, Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews.

A variety of keywords were used either alone or in combinations to identify the studies. This included references to hip infections (total hip replacement; THR; periprosthetic hip infection, hip arthroplasty infection), knee infections (total knee replacement; TKR; periprosthetic knee infection, knee arthroplasty infection), general joint infections (PJI, PPI), and "risk factors". We did not use specific keywords to search for individual risk factors, such as diabetes, *etc*.

Studies were only included if the risk factors were calculated by involving greater than 20 patients in their study cohort, and there was clear documentation of the statistical parameter used, and were only included if the P-value was quoted and one or more of the following; hazard ratio (HR), relative risk (RR), or/and odds ratio. Studies were excluded if they referred to recurrent infection following a revision procedure, hip or knee fracture, and a risk factor was excluded if the *P*-value was greater than 0.05. Results from combined studies, as seen in meta-analysis, were also excluded.

Two investigators, DAG and CLR, independently searched and reviewed the literature and determined if the study should be included based on their title and abstract. Once the two lists were compared, if the same material was presented in more than one study, only the most recent one was included.

The quality assessment criteria for the inclusion of the individual studies was adapted from George et al\[[@B7]\]. to reflect the information we expect to be present in each study. Therefore we evaluated the presence of (1) record bias reflecting the source of data, and whether the analysis was retrospective or prospective; and (2) reporting bias; each study's definition of PJI (the measured outcome).

Figure [1](#F1){ref-type="fig"} demonstrates the overall selection process according to the Prisma model\[[@B8]\]. DAG, CLR, SS and EG compared the overall findings and any discrepancies were solved by reclassification as mutually agreed.

![Flowchart summarizing the results of the literature search. RR: Relative risk; HR: Hazard ratio; OR: Odds ratio.](WJO-8-400-g001){#F1}

RESULTS
=======

Included studies
----------------

In all, 27 original studies reviewing risk factors relating to primary total hip and knee arthroplasty infections were included. The number of risk factors identified ranged from 1 to 18. Four studies (14.8%) reviewed PJI on the hip, 3 (11.21%) on the knee, and 20 (74.1%) reviewed both joints. The statistical methods used to determine significance are also shown in Table [1](#T1){ref-type="table"}\[[@B4],[@B5],[@B9]-[@B33]\].

###### 

Study characteristics including number of patients, statistical method used, site (hip, knee or both), and duration of patient follow-up

  **Ref**.                              **Year**   **Patients (*n*)**   **Statistical method used**   **Site**   **Follow-up (mo)**                     
  ------------------------------------- ---------- -------------------- ----------------------------- ---------- -------------------- ------ ---- ----- ------
  Berbari et al\[[@B9]\]                1998       462                  462                           924        OR, CI, *P*          Both   \-   \-    \-
  Lai et al\[[@B10]\]                   2007       51                   \-                            \-         OR, CI, *P*          Both   \-   84    \-
  Parvizi et al\[[@B11]\]               2007       78                   156                           234        OR, CI, *P*          Both   \-   \-    \-
  Pulido et al\[[@B12]\]                2008       63                   9182                          9245       HR, CI, *P*          Both   12   72    43
  Malinzak et al\[[@B13]\]              2009       43                   8451                          8494       OR, *P*              Both   24   192   74.4
  Ong et al\[[@B14]\]                   2009       887                  39042                         39929      OR, *P*              Hip    \-   108   \-
  Berbari et al\[[@B5]\]                2010       339                  339                           678        OR, CI, *P*          Both   \-   \-    \-
  Peel et al\[[@B15]\]                  2011       63                   126                           189        OR, CI, *P*          Both   \-   \-    \-
  Bozic et al\[[@B16]\]                 2012       \-                   \-                            40919      HR, CI, *P*          Hip    12   \-    \-
  Jämsen et al\[[@B17]\]                2012       52                   7129                          7181       HR, CI, *P*          Both   0    12    12
  Bozic et al\[[@B4]\]                  2012       \-                   \-                            83011      OR, CI, *P*          Knee   12   \-    \-
  Dale et al\[[@B18]\]                  2012       2778                 429390                        432168     RR, CI, *P*          Hip    0    60    60
  Greenky et al\[[@B19]\]               2012       389                  15333                         15722      OR, CI, *P*          Both   36   108   62.4
  Namba et al\[[@B20]\]                 2013       404                  55812                         56216      HR, CI, *P*          Knee   \-   \-    \-
  Somayaji et al\[[@B21]\]              2013       5                    254                           259        OR, CI, *P*          Both   12   124   24
  Coelho-Prabhu et al\[[@B22]\]         2013       339                  339                           678        OR, CI, *P*          Both   2    24    \-
  Maoz et al\[[@B23]\]                  2014       47                   3625                          3672       OR, CI, *P*          Hip    12   48    24
  Gómez-Lesmes et al\[[@B24]\]          2014       32                   1299                          1331       OR, CI, *P*          Knee   \-   3     \-
  Yi et al\[[@B25]\]                    2014       126                  375                           501        OR, CI, *P*          Both   3    \-    \-
  Wu et al\[[@B26]\]                    2014       45                   252                           297        OR, CI, *P*          Both   12   144   28
  Sousa et al\[[@B27]\]                 2014       43                   2454                          2497       OR, CI, *P*          Both   1    12    12
  Jiang et al\[[@B28]\]                 2014       \-                   \-                            306946     HR, *P*              Hip    6    \-    \-
  2014                                  \-         \-                   573840                        HR, *P*    Knee                 6      \-   \-    
  Duchman et al\[[@B29]\]               2015       8062+                70129+                        78191      OR, CI, *P*          Both   \-   \-    \-
  Chrastil et al\[[@B30]\]              2015       \-                   \-                            13272      HR, CI, *P*          Both   24   120   \-
  Crowe et al\[[@B31]\]                 2015       26                   3393                          3419       OR, CI, *P*          Both   \-   12    \-
  Debreuve-Theresette et al\[[@B32]\]   2015       45                   90                                       OR, CI, *P*          Both   \-   \-    \-
  Bohl et al\[[@B33]\]                  2015       \-                   \-                            49603      RR, CI, *P*          Both   \-   1     \-

RR: Relative risk; HR: Hazard ratio; OR: Odds ratio.

The quality of the included studies is demonstrated in Table [2](#T2){ref-type="table"}. Nineteen studies (70.4%) were retrospective and 8 (29.6%) prospective. Record bias was identified in the majority of studies (66.7%). The definition of PJI varied amongst the studies but there was a general consensus to define infection by previously validated methods.

###### 

Paper quality, defined by presence of record and reporting bias

  **Ref**.                                               **Design**      **Record bias**   **Reporting bias (outcome measure); definition of infection**
  ------------------------------------------------------ --------------- ----------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Berbari et al\[[@B9]\]                                 Retrospective   No                2 or more cultural examination positive for the same microorganism; sinus tract; purulence around the prosthesis/joint
  Lai et al\[[@B10]\]                                    Retrospective   No                2 or more cultural examination positive for the same microorganism; clinical diagnosis
  Parvizi et al\[[@B11]\]                                Prospective     No                Criteria based upon 3 of 5 features[1](#T2FN1){ref-type="table-fn"}
  Pulido et al\[[@B12]\]                                 Retrospective   Yes               Criteria based upon 3 of 5 features[1](#T2FN1){ref-type="table-fn"}
  Malinzak et al\[[@B13]\]                               Retrospective   No                Unknown
  Ong et al\[[@B14]\]                                    Retrospective   Yes               Diagnostic code in Medicare database
  Berbari et al\[[@B5]\]                                 Prospective     Yes               2 or more cultural examination positive for the same microorganism; acute inflammation on histopathological examination; sinus tract; purulence around the prosthesis/joint
  Peel et al\[[@B15]\]                                   Prospective     Yes               Criteria based upon 3 of 5 features[1](#T2FN1){ref-type="table-fn"}
  Bozic et al\[[@B16]\]                                  Retrospective   Yes               Diagnostic code in Medicare database
  Jämsen et al\[[@B17]\]                                 Prospective     Yes               CDC definition of surgical site infection[3](#T2FN3){ref-type="table-fn"}
  [1](#T2FN1){ref-type="table-fn"}Bozic et al\[[@B4]\]   Retrospective   Yes               Diagnostic code in Medicare database
  Dale et al\[[@B18]\]                                   Retrospective   Yes               Clinical as reported by the surgeon after surgery
  Greenky et al\[[@B19]\]                                Retrospective   No                Criteria based upon 3 of 5 features[1](#T2FN1){ref-type="table-fn"}
  Namba et al\[[@B20]\]                                  Retrospective   Yes               CDC definition of surgical site infection[3](#T2FN3){ref-type="table-fn"}
  Somayaji et al\[[@B21]\]                               Retrospective   No                Criteria based upon 3 of 5 features[1](#T2FN1){ref-type="table-fn"}
  Coelho-Prabhu et al\[[@B22]\]                          Retrospective   Yes               2 or more cultural examination positive for the same microorganism; sinus tract; purulence around the prosthesis/joint
  Maoz et al\[[@B23]\]                                   Retrospective   Yes               CDC definition of surgical site infection[3](#T2FN3){ref-type="table-fn"}
  Gómez-Lesmes et al\[[@B24]\]                           Prospective     Yes               Criteria based upon 3 of 5 features[1](#T2FN1){ref-type="table-fn"}
  Yi et al\[[@B25]\]                                     Retrospective   No                Criteria based upon 3 of 5 features[1](#T2FN1){ref-type="table-fn"}
  Wu et al\[[@B26]\]                                     Retrospective   Yes               MSIS definition[2](#T2FN2){ref-type="table-fn"}
  Sousa et al\[[@B27]\]                                  Retrospective   No                Criteria based upon 3 of 5 features[1](#T2FN1){ref-type="table-fn"}
  Jiang et al\[[@B28]\]                                  Prospective     Yes               Diagnostic code in Medicare database
  Duchman et al\[[@B29]\]                                Prospective     Yes               Criteria based upon 3 of 5 features[1](#T2FN1){ref-type="table-fn"}
  Chrastil et al\[[@B30]\]                               Retrospective   Yes               Diagnostic code in Medicare database
  Crowe et al\[[@B31]\]                                  Retrospective   Yes               CDC definition of surgical site infection[3](#T2FN3){ref-type="table-fn"}
  Debreuve-Theresette et al\[[@B32]\]                    Retrospective   No                CDC definition of surgical site infection[3](#T2FN3){ref-type="table-fn"}
  Bohl et al\[[@B33]\]                                   Prospective     Yes               American College of Surgeons National Surgical Quality Improvement Program definition

Refers to 3 of 5 of the following criteria: (1) abnormal serology (ESR \> 30 mm/h; CRP \> 1 mg/dL); (2) strong clinical and radiographic suspicion for infection; (3) positive joint aspiration culture for infection; (4) evidence of purulence during the subsequent surgical intervention; and (5) positive intraoperative culture;

Musculoskeletal Infection Society (MSIS) definition;

Defined as (1) deep infection; (2) purulent drainage; (3) dehiscence; (4) fever; and (5) localized pain. CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate.

This included the presence of 2 or more cultural positive results for the same microorganism (plus other features on infection) in 4 studies (14.8%), the CDC definition in 5 studies (18.5%), the Medicare code for infection in 5 studies (18.5%), and 9 studies (33.3%) based their definition on patients meeting 3 of the following 5 features; (1) abnormal serology (ESR \> 30 mm/h; CRP \> 1 mg/dL); (2) strong clinical and radiographic suspicion for infection; (3) positive joint aspiration culture for infection; (4) evidence of purulence during the subsequent surgical intervention; and (5) positive intraoperative culture.

One study used the MSIS criteria, which includes: (1) a sinus tract; (2) positive culture results from 2 or more tissue or fluid samples; and (3) 4 of the following 6 criteria are present: (I) elevated CRP/ESR; (II) elevated synovial WCC; (III) high synovial PMN leukocyte percentage; (IV) presence of purulence in the joint; (V) positive culture result from one sample from the affected joint; and (VI) PMN leukocyte count of more than 5 per high-powered field in 5 high-powered fields on histologic analysis at 400 × magnification\[[@B34]\].

Host-related risk factors
-------------------------

Risk factors relating to the host have been shown in Table [3](#T3){ref-type="table"}, and are the most abundant group of risk factors identified. The majority of the risk factors are systemic referring to patient co-morbidities that are negatively associated with patient outcome following a primary THR or TKR, such as presence of diabetes mellitus\[[@B4],[@B9],[@B17],[@B20],[@B26]\], immunocompromised\[[@B5],[@B15],[@B21]\], concomitttent systemic infection\[[@B5],[@B10],[@B27],[@B31]\], cardiology\[[@B4],[@B16],[@B21]\] and gastroenterology disorders\[[@B22],[@B28]\], high ASA (American Society of Anesthesiologists) grade\[[@B12],[@B15],[@B20]\] and malnutrition\[[@B13],[@B17],[@B21],[@B23],[@B25],[@B26],[@B33]\].

###### 

Host-related risk factors

                                        **Ref**.   **Statistical parameter**   **Site**                                  
  ------------------------------------- ---------- --------------------------- ---------- ----- ------------ ----------- ----------
  General                                                                                                                
  Age: 65-75 yr (compared to 45-65)     \[26\]                                 3.36             1.30-8.69    0.013       Hip/knee
  Comorbidities (total number)          \[10\]                                 1.35             1.10-1.66    0.005       Hip/knee
  Charlson index + 5 (compared to 0)    \[14\]                                 2.57             1.96-3.37    \< 0.001    Hip
  Place of residence (rural)            \[26\]                                 2.63             1.13-6.10    0.025       Hip/knee
  Hispanic race (compared to White)     \[20\]     0.69                                         0.49-0.98    0.038       Knee
  Alcohol abuse                         \[26\]                                 2.95             1.06-8.23    0.039       Hip/knee
  Tobacco use                           \[29\]                                 1.47             1.21-1.78    0.001       Hip/knee
                                        \[31\]                                 3.4              1.23-9.44    0.029       Hip/knee
                                        \[32\]     3.91                        3.4              1.19-12.84   0.032       Hip/knee
  Tobacco use (S aureus colonization)   \[23\]                                 12.76            2.47-66.16   0.017       Hip
  Gender                                                                                                                 
  Female                                \[14\]                                 0.83                          0.009       Hip
  Male                                  \[18\]                                            1.9   1.80-2.10    \< 0.001    Hip
                                        \[20\]     1.89                                         1.54-2.32    \< 0.001    Knee
                                        \[31\]                                 3.55             1.60-7.84    0.002       
  Endocrine disorders                                                                                                    
  Diabetes mellitus                     \[4\]                                  1.19             1.06-1.34    0.0025      Knee
                                        \[26\]                                 5.47             1.77-16.97   0.003       Hip/knee
                                        \[22\]     1.46                                         1.27-1.68    0.0007      Hip
                                        \[9\]                                  4                1.13-14.18   0.032       Hip/knee
                                        \[20\]     1.28                                         1.03-1.60    0.025       Knee
                                        \[17\]     2.31                                         1.12-4.72    \< 0.001    Hip/knee
                                        \[15\]                                 1.4              0.90-2.10    0.06        Hip/knee
                                        \[5\]                                  1.8              1.20-2.80    0.006       Hip/knee
                                        \[13\]                                 3.1                           0.02        Hip/knee
                                        \[44\]                                 2.21             1.34-3.64    0.001       Knee
  Pre-op BM \> 6.9 mmol/L               \[17\]     2.25                                         0.60-8.50    0.073       Hip/knee
  Pre-operative hyperglycemia           \[30\]     1.44                                         1.09-1.89    0.008       Hip/knee
  Psychiatric disorders                                                                                                  
  Depression                            \[4\]                                  1.28             1.08-1.51    0.0035      Knee
                                        \[16\]     1.6                                          1.32-1.93    0.0039      Hip
  Psychosis                             \[16\]     1.74                                         1.38-2.20    0.0044      Hip
                                        \[4\]                                  1.26             1.02-1.57    0.0331      Knee
  Haematological disorders                                                                                               
  Preoperative anaemia                  \[16\]     1.36                                         1.15-1.62    0.0005      Hip
                                        \[19\]                                 1.95             1.41-2.69    \< 0.001    Hip/knee
                                        \[4\]                                  1.26             1.09-1.45    0.0014      Knee
  Coagulopathy                          \[16\]     1.58                                         1.24-2.01    0.0002      Hip
  Malignancy                                                                                                             
  Metastatic malignancy                 \[4\]                                  1.59             1.03-2.47    0.0369      Knee
  Tumour 5 yr before implant            \[5\]                                  3.1              1.30-7.20    \< 0.01     Hip/knee
  Cardiovascular disorders                                                                                               
  Congestive heart failure              \[4\]                                  1.28             1.13-1.46    \< 0.0001   Knee
                                        \[16\]     1.57                                         1.33-1.84    0.0409      Hip
  Cardiac arrhythmia                    \[16\]     1.48                                         1.30-1.70    0.0012      Hip
  Coronary artery disease               \[21\]                                 5.10             1.30-19.8    0.017       Hip/knee
  Valvular disease                      \[4\]                                  1.15             1.01-1.31    0.039       Knee
  Peripheral vascular disease           \[4\]                                  1.13             1.01-1.27    0.0381      Knee
                                        \[16\]     1.44                                         1.24-1.68    0.0032      Hip
  Gastroenterology disorders                                                                                             
  Liver cirrhosis                       \[28\]     5.4                                                       \< 0.001    Hip
                                        \[28\]     3.4                                                       \< 0.001    Knee
  Hepatitis B virus (amongst males)     \[44\]                                 4.32             1.85-10.09   \< 0.001    Knee
  OGD with biopsy                       \[22\]                                 2.8              1.10-7.10    0.03        Hip/knee
  Respiratory disorders                                                                                                  
  Chronic pulmonary disease             \[4\]                                  1.22             1.10-1.36    \< 0.0001   Knee
                                        \[31\]                                 4.34             1.28-14.70   0.041       Both
  Pulmonary circulation disorders       \[4\]                                  1.42             1.06-1.91    0.0205      Knee
  Renal disorders                                                                                                        
  Renal disease                         \[4\]                                  1.38             1.11-1.71    0.0038      Knee
  Renal function (mL/min)               \[15\]                                 1                0.90-1.00    0.05        Hip
  Rheumatoid arthritis                                                                                                   
  Rheumatoid arthritis                  \[15\]                                 3.3              0.80-13.90   0.09        Hip/knee
                                        \[4\]                                  1.18             1.02-1.37    0.0277      Knee
                                        \[16\]     1.71                                         1.42-2.06    \< 0.0001   Hip
  ASA grade                                                                                                              
  ASA score                             \[15\]                                 2.2              1.30-4.00    0.006       Hip/knee
  Mean score                            \[11\]                                 2.07             1.08-1.97    0.03        Hip/knee
  3 (compared to 1 or 2)                \[20\]     1.65                                         1.33-2.00    \< 0.001    Knee
  \> 4                                  \[12\]     1.95                                         1.00-3.70    0.04        Hip/knee
  Body mass index                                                                                                        
  Obesity                               \[4\]                                  1.22             1.03-1.44    0.0219      Knee
                                        \[16\]     1.73                                         1.35-2.22    \< 0.0001   Hip
  BMI (kg/m^2^)                         \[15\]                                 1.1              1.00-1.10    0.05        Hip
                                        \[12\]     3.23                                         1.60-6.50    0.001       Hip/knee
  \< 20                                 \[21\]                                 6                1.20-30.9    0.033       Hip/knee
  25-30                                 \[5\]                                  0.4              0.30-0.70    \< 0.001    Hip/knee
  ≥ 28 (compared to 18.5-28)            \[26\]                                 2.77             1.20-6.40    0.017       Hip/knee
  31-39                                 \[5\]                                  0.5              0.30-0.70    \< 0.001    Hip/knee
  35 (compared to \< 35)                \[20\]     1.47                                         1.17-1.85    0.001       Knee
                                        \[32\]     1.84                                         1.11-3.05    0.007       Both
  \> 40                                 \[23\]                                 4.13             1.30-12.88   0.01        Hip
                                        \[13\]                                 3.3                           0.045       Knee
                                        \[17\]     6.41                                         1.67-24.59   \< 0.001    Hip/knee
  \> 50                                 \[13\]                                 18.3                          \< 0.001    Hip/knee
  Malnutrition                          \[25\]                                 2.3              1.50-3.50    \< 0.001    Hip/knee
  Serum albumin \< 3.5 g/dL             \[33\]                                 2                1.50-2.80    \< 0.001    Hip/knee
  Immunocompromise                                                                                                       
  Immunocompromise                      \[5\]                                  2.2              1.60-3.00    \< 0.001    Hip/knee
  Inflammatory disease                  \[18\]                                            1.4   1.10-1.70    0.001       Hip
  Prednisone dose exceeds 15 mg/d       \[21\]                                 21               3.50-127.2   \< 0.001    Hip/knee
  Systemic steroid therapy              \[15\]                                 3.3              0.80-13.90   0.09        Hip/knee
  Infection                                                                                                              
  Distant organ infection               \[5\]                                  2.2              1.50-3.25    \< 0.001    Hip/knee
  Nasal *S. Aureus* Infection           \[31\]                                 3.95             1.80-8.71    \< 0.001    Hip/knee
  Nasal MRSA Infection                  \[31\]                                 8.24             3.23-21.02   \< 0.001    Hip/knee
  Asymptomatic bacteriuria              \[27\]                                 3.23             1.67-6.27    0.001       Hip/knee
  Genitourinary infection               \[10\]                                 2.8              1.01-7.77    0.048       Hip/knee
  Operative indication                                                                                                   
  Hip fracture                          \[18\]                                            2.1   1.90-2.40    \< 0.001    Hip
  Post-traumatic osteoarthritis         \[20\]     3.23                                         1.68-6.23    \< 0.001    Knee
  Prior operation on the index joint    \[5\]                                  1.9              1.30-2.60    \< 0.001    Hip/knee
  Per additional surgery                \[32\]                                 2.88             1.45-5.80    0.018       Hip/knee
  Avascular necrosis                    \[18\]                                            1.7   1.40-2.10    \< 0.001    Hip

RR: Relative risk; HR: Hazard ratio; OR: Odds ratio.

Patient demographics also have been shown to have an impact upon risk of PJI, including age\[[@B16]\], rural residence\[[@B16]\], race\[[@B20]\], male gender\[[@B14],[@B18],[@B20],[@B31]\], and alcohol\[[@B26]\] or tobacco use\[[@B23],[@B29],[@B31],[@B32]\]. Previous operations to the joint (excluding revisions arthroplasty as this was excluded from analysis) increased the risk of PJI\[[@B5],[@B32]\].

Provider-related risk factors
-----------------------------

Risk factors relating to the provider are shown in Table [4](#T4){ref-type="table"}. Prolonged operative duration of greater than 115 minutes in hip arthroplasty is a strong predictor of infection\[[@B5],[@B14],[@B23]\], as is non-same day surgery\[[@B23]\]. During knee arthroplasty, exposure to the joint requiring quadriceps release significantly increases the risks of infection\[[@B20]\].

###### 

Provider-related risk factors

                                            **Ref**.   **Statistical parameter**   **Site**                                  
  ----------------------------------------- ---------- --------------------------- ---------- ----- ------------ ----------- ----------
  Antibiotic use                                                                                                             
  Antibiotic surgical prophylaxis           \[5\]                                  0.5              0.30-0.80    0.003       Hip/knee
  Antibiotic irrigation                     \[20\]     0.67                                         0.48-0.92    0.014       Knee
  Surgical technique                                                                                                         
  Exposure requiring quadriceps release     \[20\]     4.76                                         1.18-19.21   0.029       Knee
  Use of wound drain tube                   \[15\]                                 0.09             0.01-0.80    0.03        Knee
  Side of surgery                                                                                                            
  Simultaneous bilateral surgery            \[12\]     5.85                                         2.50-13.90   \< 0.0001   Hip/knee
                                            \[20\]     0.51                                         0.31-0.83    0.007       Knee
  Single side (compared to bilateral)       \[13\]                                 3.1                           0.0024      Hip/knee
                                            \[13\]                                 4                             0.009       Knee
  Cement                                                                                                                     
  Antibiotic-laden cement                   \[20\]     1.53                                         1.18-1.98    \< 0.001    Knee
  Non-antibiotic cement                     \[8\]                                             1.5   1.30-1.80    \< 0.001    Hip
  Hybrid (compared to uncemented)           \[8\]                                             1.6   1.40-1.80    \< 0.001    Hip
  Operative duration                                                                                                         
  Length of operation (\> 115 min)          \[23\]                                 3.38             1.23-9.28    0.018       Hip
  (\> 210 min)                              \[14\]                                 1.78             1.40-2.26    \< 0.0001   Hip
  (≥ 240 min)                               \[5\]                                  2.7              1.50- 5.00   0.002       Hip/knee
  Hospital factors                                                                                                           
  Hospital volume \< 100 (*vs* \> 200/yr)   \[20\]     0.33                                         0.12-0.90    0.03        Knee
  Medicare buy-in                           \[14\]                                 1.34                          0.005       Hip

RR: Relative risk; HR: Hazard ratio; OR: Odds ratio.

Protective measures include the use of antibiotic surgical prophylaxis systemically\[[@B5]\] and locally as irrigation\[[@B20]\], but antibiotic impregnated cement may or may not be protective\[[@B18],[@B20]\]. In addition, bilateral procedures during the same operation have been shown by some studies to increase the risk\[[@B12]\], whilst in others decrease it\[[@B20]\].

Post-surgical risk factors
--------------------------

Post-operatively patients may present with a superficial infection to the joint with a warm, cellulitic, and sometimes discharging wound, which is a high predictor of an underlying PJI\[[@B5],[@B11],[@B9],[@B15]\]. Table [5](#T5){ref-type="table"} demonstrates other factors that have a high correlation with a PJI, including receiving a blood transfusion\[[@B11],[@B12],[@B15]\] (especially if the blood has been stored for greater than 14 d\[[@B24]\]), post-operative urinary tract infection (UTI)\[[@B5],[@B12]\], and onset of cardiac arrhythmias\[[@B12]\].

###### 

Post-surgical risk factors

                                                **Ref**.   **Statistical parameter**   **Site**                             
  --------------------------------------------- ---------- --------------------------- ---------- ------------- ----------- ----------
  Anaesthetic factors                                                                                                       
  Intensive care length of stay (d)             \[15\]                                 0.5        0.20-1.00     0.06        Knee
  Haematological                                                                                                            
  Blood transfusion                             \[12\]     2.11                                   1.10-3.90     0.02        Hip/knee
                                                \[15\]                                 2.1        1.00-4.20     0.04        Hip/knee
                                                \[11\]                                 1.63       1.14-2.33     0.007       Hip/knee
  Transfusion if RBCs stored \> 14 d            \[24\]                                 5.9        2.60-13.20    \< 0.001    Knee
  Perioperative blood loss (*via* drain tube)   \[15\]                                 1          1.00-1.01     0.008       Hip
  Cardiac                                                                                                                   
  Postoperative atrial fibrillation             \[12\]     6.22                                   1.40-28.5     0.02        Hip/knee
  Postoperative myocardial infarction           \[12\]     20.4                                   2.10-199.9    0.009       Hip/knee
  Hospital factors                                                                                                          
  Longer hospital stay                          \[12\]     1.09                                   1.00-1.10     0.0003      Hip/knee
  Non same-day surgery                          \[23\]                                 4.16       1.44-12.02    0.008       Hip
  Wound complications                                                                                                       
  All wound complications                       \[11\]                                 27         11.00-91.6    0.0002      Hip/knee
  Wound discharge                               \[5\]                                  18.7       7.40-47.2     \< 0.001    Hip/knee
                                                \[15\]                                 6.3        1.30-30.7     0.02        Knee
                                                \[15\]                                 5.4        2.00-15.0     0.001       Hip
                                                \[15\]                                 5.7        2.40-13.3     \<0.001     Hip/knee
                                                \[11\]                                 32.2       8.7-119.17    \< 0.0001   Hip/knee
  Haematoma                                     \[5\]                                  3.5        1.30-9.50     0.01        Hip/knee
  Surgical site infection                       \[1\]                                  35.9       8.30-154.6    \< 0.01     Hip/knee
  Superficial incisional SSI                    \[15\]                                 3.7        1.10-11.9     0.03        Knee
                                                \[15\]                                 5          1.60-15.9     0.007       Hip
                                                \[15\]                                 4.3        1.90 - 9.90   0.001       Hip/knee
  NNIS risk index 2                             \[9\]                                  3.9        2.00-7.50     \< 0.01     Hip/knee
  Urinary                                                                                                                   
  Postoperative urinary infection               \[12\]     5.45                                   1.00-8.70     0.04        Hip/Knee
                                                \[5\]                                  2.7        1.04-7.10     0.04        Hip/Knee

RR: Relative risk; HR: Hazard ratio; OR: Odds ratio.

Risk factor impact
------------------

Several risk factors were shown to have greater significance than others, and a vast majority of the risk factors were directly related to the patient (host-factors). The most significant risks were the use of preoperative high dose steroids (OR = 21.0, 95%CI: 3.5-127.2, *P* \< 0.001)\[[@B21]\], a BMI above 50 (OR = 18.3, *P* \< 0.001)\[[@B13]\], tobacco use (OR = 12.76, 95%CI: 2.47-66.16, *P* = 0.017)\[[@B23]\], BMI below 20 (OR = 6.00, 95%CI: 1.2-30.9, *P* = 0.033)\[[@B21]\], diabetes (OR = 5.47, 95%CI: 1.77-16.97, *P* = 0.003)\[[@B26]\], and coronary artery disease (OR = 5.10, 95%CI: 1.3-19.8, *P* = 0.017)\[[@B21]\].

Modifiable risk factors
-----------------------

We further categorised the resultant risk factors into whether or not they were modifiable, reflecting the opportunity of the surgeon to optimise their patient pre-operatively and to reduce the risk of developing a PJI (Table [6](#T6){ref-type="table"}).

###### 

Classification of risk factors and probability of infection (main factors)

                                  **Risk factor**              **Minimum increase**   **Maximum increase**   **Statistical parameter**   **Ref**.
  ------------------------------- ---------------------------- ---------------------- ---------------------- --------------------------- -----------
  Host-related risk factors                                                                                                              
  Modifiable                      Systemic steroids            3.3                    21                     OR                          \[15,21\]
                                  Tobacco use                  3.4                    12.76                  OR                          \[23,32\]
                                  Nasal MRSA infection         \-                     8.24                   OR                          \[31\]
                                  BMI \< 20                    \-                     6                      OR                          \[21\]
                                  Coronary artery disease      \-                     5.1                    OR                          \[21\]
                                  COPD                         1.22                   4.34                   OR                          \[4,31\]
                                  BMI \> 40                    \-                     4.13                   OR                          \[23\]
                                  Pre-operative BM             \-                     2.25                                               \[17\]
  Non-modifiable                  Diabetes                     1.4                    5.47                   OR                          \[15,26\]
                                  Liver cirrhosis              \-                     5.4                    HR                          \[28\]
                                  Male                         1.89                   3.55                   HR,OR                       \[20,31\]
                                  Age                          \-                     3.36                   OR                          \[26\]
                                  Rheumatoid arthritis         1.18                   3.3                    OR                          \[4,15\]
                                  Malignancy                   \-                     3.1                    OR                          \[5\]
  Provider-related risk factors                                                                                                          
  Modifiable                      Quadriceps release (TKR)     \-                     4.76                   HR                          \[20\]
                                  Non-same day procedure       \-                     4.16                   OR                          \[23\]
                                  Prolonged operation          1.78                   3.38                   HR                          \[14,23\]
  Non-modifiable                  Prolonged storage of blood   2.6                    13.2                   OR                          \[24\]

BMI: Body mass index; RR: Relative risk; HR: Hazard ratio; OR: Odds ratio; COPD: Chronic obstructive pulmonary disease; TKR: Total knee replacement.

DISCUSSION
==========

It is extremely difficult to predict if a patient will develop a post-operative infection following lower limb arthroplasty. Multiple prospective and retrospective studies have reviewed the risks associated with their patient cohort developing such infections. This paper was undertaken to combine these risks and determine if there was a consensus to which factors puts a patient at highest risk, and categorise them if they related directly to the host (patient), provider (the surgical team and their Institute), or occurred during the post-operative period.

Little is known about the interaction between, or synergistic effect, of specific patient risk factors\[[@B35]\], as it is likely they have a multiplicity effect, rather than additive risk, as shown by Tomás\[[@B6]\]. In their cohort if a patient had two (or more) significant factors the probability of infection development was 14-times higher, whereas having three (or more) factors the probability was increased 16-times.

Several themes have emerged following this systematic review of the literature, specifically the patient's immunological and systematic responses to infection, other sources of infection, antibiotic use, and provider factors.

Immunological response
----------------------

The most frequently quoted risk factor was diabetes mellitus\[[@B4],[@B9],[@B17],[@B20],[@B22],[@B26]\], which had one of the highest odds ratios\[[@B26]\]. Almost all the other highest odds ratio, or hazard ratio, also belonged to medical conditions ultimately impairing a patients immunity, as demonstrated from high dose pre-operative steroids\[[@B21]\], malnutrition (reflective of high alcohol intake\[[@B26]\], BMI below 20\[[@B21]\] and above 50\[[@B13]\]), and tobacco use\[[@B23]\]. Malignancy\[[@B4],[@B5]\], rheumatoid arthritis\[[@B4],[@B15],[@B16]\], and liver cirrhosis\[[@B28]\] can also impair a patient's immunity.

Immunosuppression has long been known to increase a patient's risk of systemic infection, and has widely been documented in arthroplasty patients. Ragni et al\[[@B36]\] demonstrated this in human immunodeficiency virus-positive hemophiliacs with CD4 counts of 200 mm^3^ or less undergoing orthopaedic surgery. Post-operative infection occurred in 10 (15.1%) of 66 patients\[[@B36]\]. Local steroid injection causing focal immunosuppression about the joint has also been shown to increase the risk, compared to those that have not received any joint injections in hip arthroplasty cases\[[@B37]\].

In rheumatoid patients treated with immunosuppressive drugs (including biologic agents) undergoing all orthopeadic procedures, a statistically significant higher risk of infection was seen in this patient cohort compared to a degenerative/post-traumatic group (OR = 2.58, 95%CI: 1.91-3.48, *P* \< 0.001)\[[@B38]\]. Furthermore this risk was significantly increased in patients taking multiple disease-modifying antirheumatic drugs (DMARDs) (*P =* 0.036) or tumor necrosis factor α (TNFα) inhibitors (*P* = 0.032), especially if the last dose of TNFα inhibitor was given \< 1 administration interval before surgery\[[@B38]\].

Infection response
------------------

While not directed specifically to immunosuppression, other co-morbidities have a role in reducing the patients systemic response to infection. Cardiac dysfunction\[[@B4],[@B16],[@B21]\], renal failure\[[@B4],[@B15]\], anaemia\[[@B4],[@B9],[@B16]\] and coagulopathy\[[@B16]\] have all been shown to increase the risk of infection. This may be directed through specific cellular pathways\[[@B39]\], but may demonstrate the insult the surgical procedures has in causing a secondary inflammatory insults, worsening multiple organ dysfunction\[[@B40],[@B41]\].

Deranges in renal function, with progressively higher poor glomerular filtration rate (GFR) in either the acute or chronic stages, reduces the ability to remove unwanted and hazardous chemicals from the blood, and places the patient at a higher risk. Lieberman et al\[[@B42]\] demonstrated a high rates of infection in patients on chronic renal dialysis (19%), however in a separate patient series no significant increase in infection risk was seen\[[@B43]\].

Infection source
----------------

We believe that if a patient is known to have systemic infection, or a localised infection but distant to the operative joint, the risk of haematological spread of infection to the implant is highly likely. We have demonstrated a statistically significant increased risk of PJI in patients with a pre-operative confirmation of a genitourinary infection\[[@B10],[@B27]\], nasal *S. Aureus* and *MRSA* infections\[[@B31]\], or other distant organ infections\[[@B6]\], such as hepatitis B\[[@B44]\].

Conditions that further increase this risk are those that may make the patient more susceptible for the introduction of a new pathogen, such as chronic pulmonary disease\[[@B4],[@B31]\] with known high rates of pneumonia, peripheral vascular disease\[[@B4],[@B16]\] with high risk of skin ulceration and introduction of skin contaminates, and recent oesophagogastroduodenoscopy (EGD) with biopsy\[[@B22]\], risking the introduction of gut flora to the blood system.

Furthermore, perioperative blood transfusion increases the risk of PJI in both hip and knee arthroplasty\[[@B11],[@B12],[@B15]\], and allogeneic blood transfusion has been shown to instigate a detrimental immunomodulation reaction, and decreases T-cell-mediated immunity, and may enhance the acute inflammatory response\[[@B45],[@B46]\]. Stored blood can cause a significant increase in inflammatory cytokine release from the stored neutrophils, and superoxide release results in delaying neutrophil apoptosis and risks cytotoxicity\[[@B47],[@B48]\].

This has been confirmed in a recent systematic meta-analysis of 6 studies demonstrating the association between allogeneic blood transfusion and an increased risk for a SSI after total hip and knee arthroplasty. Data was included from over 20000 patients, and the blood transfusion group had a significantly higher frequency of infection (pooled OR = 1.71, 95%CI: 1.23-2.40, *P =* 0.002) compared to the non-exposed group\[[@B49]\].

Antibiotic use
--------------

The use of antibiotic-impregnated cement was shown by Dale et al\[[@B18]\] to protect against revisions due to infection, whereas Namba et al\[[@B20]\] identified an increased risk. Such conflicting outcomes are common in the literature regarding the use of antibiotic-impregnated cement in primary procedures. A prospective randomized study with 2948 cemented total knee arthroplasties failed to see an improvement of PJI rates by using bone cement loaded with erythromycin and colistin compared to controls\[[@B50]\], whereas the Norwegian Arthroplasty Register has demonstrated a synergistic effect of systemic and cement antibiotics\[[@B51]\]. However there is a general consensus that antibiotic-impregnated cement has a greater role in revision cases\[[@B52]\], and is recommended as standard practice in these high-risk cases\[[@B53]\].

Systemic antibiotics given at anaesthetic induction are generally the standard of care, and continued post-operatively for a further two doses in the United Kingdom, and for two days in Italy (authors experience). The choice of antibiotic varies in each Institute to reflect the prominent pathogen and patient cohort. Multiple studies have demonstrated the benefits of antibiotics given during the procedure to reduce the risk of post-operative infection\[[@B51],[@B54]\].

Provider factors
----------------

Concerning the relative impact of the hospitals yearly volume of procedures, we found only one retrospective review of joint registry data, that suggests that the fewer total knee arthroplasties undertaken per year will result in a lower rate of infection\[[@B20]\]. This particular finding needs, in our opinion, further validation, since it contradicts other reports demonstrating better outcomes from greater volumes of surgery and greater experience of the surgeons, as exemplified by the Hospital for Special Surgery, New York\[[@B55]\], while other studies have shown no difference between the two\[[@B56]\].

Furthermore, the use of a drain post-operatively has been shown by Peel et al\[[@B15]\] to reduce the risk of PJI following knee arthroplasty, however multiple meta-analyses and prospective, randomised, controlled trials have demonstrated no significant difference in post-operative infections between the wounds treated with a drain and those without\[[@B57],[@B58]\].

Modifiable risk factors
-----------------------

When the risk factors were further categorised into modifiable or not, the vast majority of factors were non-modifiable. Many risk factors increased a patient's risk by less than 5 times (OR \< 5), and very few increased the risk by more than 10 times.

However, the presence of non-modifiable risk factors still requires attention, and may be more important than modifiable ones. Alternate methods should be adopted to reduce the patient's burden and may include a combination of implant modifications (such as silver or disposable microbiological coatings)\[[@B59],[@B60]\], antibiotic impregnated cement or bone graft\[[@B61],[@B62]\], or other novel therapies\[[@B63]\] to provide a personalized and more effective prophylaxis.

It is the responsibility of the operating team to act upon these, and modify or optimise the patient prior to surgery. For example, intensive insulin therapy, maintaining tight blood glucose concentrations between 80 and 110 mg/dL, has been shown to decrease infection-related complications and mortality\[[@B64]\]. Normal renal function should be sought, nutrition improved, cardiac investigations and interventions should be offered, local and systemic infections appropriately treated, as should chronic anaemia, and patients should be informed to withhold DMARDs and stop tobacco smoking and alcohol use preoperatively.

Risk-analysis tools
-------------------

Indeed, determining individual patients risks is an important step in personalized informed consent. Surgeons may quote published rates or their own, but the risk is individual and should reflect all the aforementioned factors, which may have consequences in the medico-legal evaluation in case of damage evaluation after PJI.

Previous attempts to combine such measures in a scoring system have been attempted by The Mayo Clinic\[[@B65]\] who based the data on their cohort of patients at baseline and at one month. Bozic et al\[[@B35]\] developed a risk calculator using data from 11 years worth of Medicare claims. A similar tool has been developed in the Chinese population\[[@B26]\].

The main disadvantage of such tools is the calculations relate to a specific set of patients, and may not reflect the general public risks, as they have not been externally validated. In addition the data is unlikely to appreciate advances in perioperative care over the time period, and may not capture patients with late onset PJI if follow-up is short.

Limitations
-----------

A wide variety of studies were included in this systematic review, which gives an overview of risk factors for hip and knee PJI but the quality of each study is generally poor. As previously discussed, only 8 studies (29.6%) were prospective, and one third of studies demonstrated record bias. Reporting bias was also seen amongst the studies, as a variety of diagnostic criteria were used. This is common amongst studies reviewing PJI as there is no gold standard measure to determine presence of infection, nor an agreement to the medical, or surgical management, for these patients\[[@B53]\].

Our search criteria only highlighted studies with "risk factor" in the title, and therefore we did not search for studies looking at individual risk factors. Therefore studies, some of high quality, may not have met our inclusion criteria. Furthermore, we were unable to undertake a meta-analysis due to the heterogeneity of the data.

In conclusion, as demonstrated, current data is conflicting as the influence of the risk factors vary widely, and we believe more emphasis is required regarding the multiplicity effects of risk factors. We need larger studies and novel tools to investigate single and combined risk factors, and to identify key areas of improvement and modification for these patients.

The literature has demonstrated significant variation in the number and type of risk factors that places a patient at higher risk of developing a PJI, which is heavily weighted towards the patient. However the provider has a role in addressing the modifiable risk factors pre-operatively to optimise their patient, and develop new strategies to limit the impact of non-modifiable factors.

COMMENTS
========

Background
----------

Several studies have previously shown the impact of various risk factors on the probability of developing an infection after joint replacement. The heterogeneity of the available data notwithstanding, in this systematic review a detailed analysis of the respective weight of known risk factors, classified as host-, provider- or post-surgical-related, is performed; moreover, a further distinction in modifiable or not-modifiable risk factors is proposed.

Research frontiers
------------------

A classification and ranking of known risk factors may open new frontiers in prevention and control of peri-prosthetic infections. Furthermore, it can be helpful to improve the information to the patient prior to surgery, to drive personalised prophylaxis and to better evaluate the cost-to-benefit ratio of new technologies, like antibacterial coatings, designed to reduce bacterial adhesion on implanted biomaterials.

Innovations and breakthrough
----------------------------

This systematic review sheds new lights on the relative impact of various risk factors that increase a patient's risk of developing lower limb periprosthetic joint infections (PJI). This ultimately reiterates the importance of optimising the patients pre-operatively by addressing modifiable risk factors (such as their immunosuppression, nutrition, diabetes, and smoking), and develops strategies to limit the impact of non-modifiable factors.

Applications
------------

The data obtained in this systematic review may form the basis for the development of specific software, like the "PJI Risk App", an application for smartphones, specifically designed to calculate the risk of developing a peri-prosthetic infection in a given patient. This in turn may be useful for surgeons and their patients to understand the specific risk of undergoing joint replacement and eventually to better tailor antibiotic prophylaxis.

Peer-review
-----------

In this manuscript authors reviewed provider risk factors of chronic PJI. This study is interesting and the objective very clear.
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